Couverture de Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive

De : Pharmaceutical Executive Podcast
Écouter gratuitement

À propos de ce contenu audio

 The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. Science
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Pharmaceutical Executive Daily: BioNTech Files Patent iInfringement Lawsuit Against Moderna

      Pharmaceutical Executive Daily: BioNTech Files Patent iInfringement Lawsuit Against Moderna
      Feb 20 2026
      In today’s Pharmaceutical Executive Daily, BioNTech files a patent infringement lawsuit against Moderna, the Supreme Court rules against a large number of Trump-era tariffs, and the FDA approves a Calquence–venetoclax combination for certain blood cancers.
      Afficher plus Afficher moins
      2 min
    • Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals

      Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals
      Feb 19 2026
      In today’s Pharmaceutical Executive Daily, the FDA reportedly removes its two-study requirement for new drug approvals, Hims & Hers enters a $1 billion agreement to acquire Eucalyptus, and experts examine how FDA can help ease early-stage clinical trial bottlenecks.
      Afficher plus Afficher moins
      2 min
    • Pharmaceutical Executive Daily: FDA Initiates Review of Moderna’s Seasonal Influenza Vaccine

      Pharmaceutical Executive Daily: FDA Initiates Review of Moderna’s Seasonal Influenza Vaccine
      Feb 18 2026
      In today’s Pharmaceutical Executive Daily, the FDA begins reviewing Moderna’s seasonal flu vaccine under a revised regulatory approach, Eli Lilly signs a $100 million licensing agreement with CSL for an anti- IL-6 monoclonal antibody., and Southern Florida emerges as a growing biotech hub.
      Afficher plus Afficher moins
      2 min
    Aucun commentaire pour le moment